ChoA Pharmaceutical Co Ltd

ChoA Pharmaceutical's capital structure shows a debt-to-equity ratio of 1.09, indicating a moderate reliance on debt financing. The company's liquidity position is weak, with a current ratio of 0.98 and negative free cash flow of -6.24 billion KRW. The negative operating cash flow of -4.18 billion KRW and negative net cash position after subtracting total debt further highlight liquidity constraints. Profitability metrics are sharply negative, with a return on equity of -27.22% and return on assets of -10.52%. These figures fall well below the typical performance of the pharmaceutical industry, which usually maintains positive ROE and ROA. The company's operating loss of 7.73 billion KRW and net loss of 6.81 billion KRW underscore a significant underperformance relative to industry norms. The company's revenue is concentrated in pharmaceuticals, quasi-drugs, and health functional foods, with no disclosed geographic diversification. This lack of segment or geographic transparency increases exposure to market-specific risks. The absence of detailed segment reporting limits the ability to assess growth drivers or underperforming areas. ChoA Pharmaceutical's growth trajectory is negative, with a net loss and declining cash flows. The company's operating income and net income are both in negative territory, and there is no indication of a turnaround in the near term. The lack of positive revenue growth or margin expansion suggests a challenging outlook for the current fiscal year. The company's risk profile is elevated due to liquidity constraints and negative profitability. The risk assessment flags a negative net cash position after subtracting total debt, which increases the likelihood of financial distress. While dilution risk is currently low, the company's capital structure and cash flow challenges could necessitate equity issuance in the future. Recent financial filings show a last actual EPS of -32.00 KRW, reflecting the company's ongoing financial difficulties. No recent transcripts or events have been disclosed that indicate a strategic shift or operational improvement.